GSK’s RSV Vaccine Prospects in Youngest Pediatric Patients Looks Unlikely, per FDA Label

GlaxoSmithKline Pharmaceuticals Ltd. won the first US approval for a respiratory syncytial virus vaccine on May 3 in older adults but looks like it may not be able to claim the same crown in the other key population impacted by the virus — infants and young children.

The Food and Drug Administration approval letter for GSK’s Arexvy says the agency is waiving the pediatric study requirement for children ages 0 to 2 “because there is evidence strongly suggesting that the biological product would be unsafe in this pediatric group.”

The label for Arexvy, which is indicated for adults 60 and older, says “evidence from an animal model strongly suggests that Arexvy would be unsafe in individuals younger than 2 years of age because of increased risk of enhanced respiratory disease.”

© 2024 MMIT
Sarah Karlin-Smith

Sarah Karlin-Smith

Sarah is a senior writer with Pink Sheet and has covered U.S. regulation and reimbursement policy for the biopharma industry since 2004, starting with the establishment of the Medicare Part D program. Since then, she has written extensively about developments in all major sectors of the U.S. insurance market (Medicare, Medicaid and commercial plans). She has covered key legislation affecting biopharma, including the Medicare Prescription Drug, Improvement, and Modernization Act which created Part D, health care reform under President Obama, and the Inflation Reduction Act. She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered developments in health technology assessments and has monitored industry progress on novel drug contracting that reflects value-based pricing.

Related Posts

October 13

Once Nonexistent, Pipeline for RSV Vaccines is Now Crowded With Contenders

February 9

2023 Outlook: Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact

August 13

Shingrix Uptake May Be Slowed By Part D Cost Sharing With Chart: Current Market Access to Shingrix

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today